Saturday 17 October 2026
Export AVR’s income statement to Excel — free account
Anteris Technologies Global Corp.
AVR Healthcare Medical Instruments & Supplies
Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024. In the quarter to June 2026, revenue grew 63.3%, EPS grew 48.3%, free cash flow fell 6.84% and total debt rose 8.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.05
0.31
−4.87%
Follow AVR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+7 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
75.87 | 96.28 | 248.89 | 427.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.89) | (9.94) | (16.06) | (46.10) | |
P/B ratio |
48.31 | 0.00 | 1.65 | 3.81 | |
Price to Tangible BV |
49.34 | 0.00 | 1.66 | 3.81 | |
EV/Sales |
71.66 | 89.73 | 96.28 | 313.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.98) | (2.21) | (2.10) | (8.14) | |
EV/FCF |
(1.93) | (2.15) | (2.05) | (7.95) | |
Quick Ratio |
0.70 | 0.59 | 20.70 | 14.05 | |
Current Ratio |
0.84 | 0.73 | 20.93 | 14.20 | |
Net Debt/EBITDA |
0.41 | 0.44 | 11.98 | 8.42 | |
Debt/Assets |
0.64% | 0.17% | 0.25% | 0.17% | |
Debt/Equity |
0.04 | (0.15) | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.04 | 0.01 | 0.01 | |
Operating CF/Net income |
0.82 | 0.63 | 1.25 | 0.71 | |
Capex/Depreciation |
(1.85) | (0.94) | (0.42) | (1.38) | |
Interest Coverage |
(1,484.33) | (2,896.50) | (889.15) | (236.62) | |
Research and Development Expense of Revenue |
3,918.41% | 6,294.84% | 3,533.81% | 2,316.06% | |
Selling, General and Administrative Expense of Revenue |
1,342.89% | 3,119.35% | 1,402.83% | 832.90% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.03) | (0.04) | 0.59 | 0.25 | |
Graham Number |
0.00 | 0.63 | 0.00 | 0.00 | |
Earnings Yield |
(57.91%) | (51.30%) | (40.18%) | (19.80%) | |
Free Cash Flow Yield |
(48.95%) | (43.30%) | (18.85%) | (9.21%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.51) | (0.50) | (0.35) | (0.21) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.53) | (0.51) | (0.35) | (0.22) | |
Cash per Share |
0.25 | 0.34 | 3.41 | 2.64 | |
Shareholders Equity per Share |
0.09 | (0.01) | 3.35 | 2.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.09 | (0.01) | 3.35 | 2.59 | |
Free Cash Flow |
(19.02) | (18.92) | (28.86) | (21.44) | |
Working Capital |
(2.21) | (5.70) | 272.98 | 242.29 | |
Capital Expenditures |
(0.77) | (0.40) | (0.18) | (0.65) | |
Net Current Asset Value |
(4.49) | (7.57) | 270.36 | 239.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.80 | 1.28 | 0.37 | 0.64 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.32 | 0.12 | 0.21 | 0.62 | |
Average Payables |
3.71 | 8.49 | 4.63 | 5.25 | |
Average Inventory |
0.44 | 0.33 | 0.24 | 0.23 | |
Average Assets |
24.80 | 51.85 | 176.76 | 156.19 | |
Average Common Equity |
11.13 | 31.21 | 160.76 | 137.85 |
Columns are period end dates